Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
anti-CD19 CAR-T in Refractory Systemic Sclerosis
NCT06792344Phase 1Suspended
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in systemic sclerosis (SSc), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Efficacy endpoint at 6 months. Started Dec 2025; status: suspended.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06792344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792344.